Trials / Completed
CompletedNCT01386983
Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 332 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This retrospective study aims to assess the clinical and economic impact of early initiation of 5-alpha-reductase inhibitor (5ARI) therapy in patients with enlarged prostate (EP) receiving 5ARI monotherapy or combination therapy with an alpha-blocker (AB) compared to late initiation of 5ARI therapy in patients receiving combination therapy. The Henry Ford Health System databases will be utilized for this study (2000-2008).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 5ARI | Dutasteride or Finasteride |
| DRUG | 5ARI + AB | 5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2011-07-01
- Last updated
- 2017-05-17
- Results posted
- 2011-07-01
Source: ClinicalTrials.gov record NCT01386983. Inclusion in this directory is not an endorsement.